期刊
TRENDS IN CARDIOVASCULAR MEDICINE
卷 26, 期 5, 页码 395-404出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcm.2016.01.003
关键词
Cardiovascular disease; Cardiopoiesis; Cardiopoietic stem cell; Clinical trial; Clinomics; Epidemic; Health care; Myocardial infarction; Next generation; Regenerative medicine; Quality; System
资金
- Marriott Foundation
- Michael S. and Mary Sue Shannon Family
- Russ and Kathy VanCleve Foundation
- Leducq Fondation
- Florida Heart Research Institute
- Celyad
- National Institutes of Health
Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next generation regenerative solution for heart failure. (C) 2016 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据